John Lepore, MD is Senior Vice President and Head of Research at GSK, responsible for research activities to discover novel medicines focusing on modulation of the immune system and leveraging human genetics to identify new drug targets. John joined GSK in 2006 and has held roles of increasing responsibility including VP of Clinical Pharmacology and Discovery Medicine, VP and Head of the Heart Failure Discovery Performance Unit, SVP and Head of the Metabolic Pathways and Cardiovascular Therapeutic Area Unit, and SVP R&D Pipeline responsible for end-to-end R&D activities across multiple therapeutic areas.
Before joining GSK, John was on the faculty of the Cardiovascular Medicine Division of the Department of Medicine at the University of Pennsylvania, where his lab investigated the transcriptional regulation of cardiovascular development and he was attending physician on the academic cardiology service. John received his BS in Biology from the University of Scranton and his medical degree from Harvard Medical School where he was a Howard Hughes Medical Institute Research Scholar. He subsequently trained in internal medicine and cardiology at Massachusetts General Hospital, with post-doctoral training at the Harvard School of Public Health.
John is on the Board of Directors of ViiV Healthcare and the Scientific Advisory Boards of Medicxi Ventures and Hatteras Ventures. At GSK, he previously chaired the Discovery Investment Board and Technology Investment Board and now chairs the Research Review Board and Research Investment Board.